DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
On raw weight loss, yes — Zepbound delivers ~22% body weight loss vs Wegovy ~15% in clinical trials. On cardiovascular outcomes evidence, Wegovy is ahead.
On raw weight loss, yes — Zepbound delivers ~22% body weight loss vs Wegovy ~15% in clinical trials. On cardiovascular outcomes evidence, Wegovy is ahead.
For pure weight loss, Zepbound (tirzepatide) is statistically superior to Wegovy (semaglutide). SURMOUNT-1 showed ~22% body weight reduction on Zepbound 15mg vs SELECT trial ~15% on Wegovy 2.4mg. The molecules differ — tirzepatide acts on both GLP-1 and GIP receptors, while semaglutide is GLP-1 only. For cardiovascular outcomes, Wegovy has the longer track record — the SELECT trial demonstrated mortality benefit over 5 years. SURPASS-CVOT data for tirzepatide is still maturing. Cash-pay pricing is similar ($549/mo via LillyDirect vs $499/mo via NovoCare). Insurance coverage typically favors Wegovy for weight loss and Zepbound when OSA-with-obesity indication applies.